Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly EBIT Margin came in at 165.75% in Q4 2025, up 76.33% on a QoQ basis from 700.35% in Q2 2025.
Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of EBIT Margin data on file, last reported at 165.75% in Q4 2025.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 165.75% in Q4 2025; TTM through Dec 2025 was 609.18%, a 5511.0% decrease from a year earlier, with the FY2025 full-year figure at 609.18%, down 5511.0% from the prior year.
- EBIT Margin for Q4 2025 stood at 165.75%, up from 700.35% in the prior quarter.
- Over the last five years, EBIT Margin for PYXS reached as high as 34.71% in Q1 2024 and fell as low as 700.35% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | -165.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -165.75% |
| Jun 30, 2025 | -700.35% |
| Mar 31, 2024 | -34.71% |